Disease & disorder

progesterone-receptor negative breast cancer

MONDO:0000616

Clinical trials15
Recruiting0
Drug concepts studied16
Synonyms0

Disease research snapshot

CureCurrent currently links 15 distinct registered clinical trials to progesterone-receptor negative breast cancer through its MONDO disease mappings. 0 of those studies have the registry status “recruiting” (0%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is National Cancer Institute (NCI), associated with 3 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is New York, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

The most frequently mapped drug concept in the current linked trials is carboplatin (4 distinct trials). This describes what has been studied, not a recommended treatment.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

progesterone-receptor negative breast cancer

Wikidata Q18553639 ↗
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

15 shown
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)NCT04504916 · 2020-10-07
TERMINATED
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerNCT02315196 · 2015-02-25
ACTIVE_NOT_RECRUITING
MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerNCT01805076 · 2014-05-21
COMPLETED
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)NCT01881230 · 2013-09-26
COMPLETED
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerNCT01818063 · 2013-04-25
COMPLETED
Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsNCT01372579 · 2011-08-01
UNKNOWN
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by SurgeryNCT01234532 · 2010-10-01
TERMINATED
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerNCT01104259 · 2010-07-01
COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerNCT01151449 · 2010-06-01
TERMINATED
Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast CancerNCT01100489 · 2010-02-01
WITHDRAWN
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerNCT01037790 · 2009-10-01
COMPLETED
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerNCT00733408 · 2008-04-23
COMPLETED
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryNCT00559507 · 2007-10-01
COMPLETED
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)NCT00031681 · 2001-12-01
COMPLETED
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerNCT00003199 · 1997-11-01
COMPLETED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.